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GSK3β and E2F1 play an important role in the control of proliferation and apoptosis. Previous work has demonstrated that GSK3β indirectly
regulates E2F activity through modulation of cyclin D1 levels. In this work we show that GSK3β phosphorylates human E2F1 in vitro at serine
403 and threonine 433, both residues localized at its transactivation domain. This phosphorylation was not detected in vivo. However, co-
immunoprecipitation experiments do reveal in vivo binding of these proteins. Moreover, uninhibitable and catalitycally inactive GSK3β forms
inhibit the transcriptional activity of a fusion protein containing E2F1 transactivation domain. Both forms of GSK3β inhibit E2F1 with similar
efficiency. Interestingly the effect was independent of the mutation of serine 403 and threonine 433 to alanine. This suggests that this
transcriptional modulation is independent of GSK3β kinase activity and phosphorylation state of serine 403 and threonine 433. The re-targeting of
these GSK3β forms to the nucleus results in a higher capacity to regulate E2F1 transcriptional activity. Depletion of the levels of GSK3β protein
using siRNA activates E2F1 transcriptional activity. The data presented in this study offer a new mechanism of regulation of E2F1 by direct
binding of GSK3β to its transactivation domain.
© 2006 Elsevier B.V. All rights reserved.Keywords: GSK3β; E2F1; Protein–protein interaction; Transcriptional activity; Transcription factor1. Introduction
The E2 factor (E2F) family of transcription factors has a
central role in cell fate decisions that connect cell proliferation,
apoptosis, differentiation and development. The diversity in
the E2F family reflects their distinct biological roles in
transcriptional regulation and cellular function. E2F1–3Abbreviations: E2F, E2 factor; pRb, retinoblastoma protein; PI 3-kinase/
PKB, phosphatidylinositol 3-kinase/protein kinase B; GSK3β, glycogen
synthase kinase-3β; hE2F, human E2F1; GST, glutathione S-transferase;
DRB, 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole; siRNA, small interfer-
ing RNA; cdk7, cyclin-dependent kinase 7; MS, mass spectrometry
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doi:10.1016/j.bbamcr.2006.09.015activate genes that are essential for progression through the
cell cycle and for induction of apoptosis. In contrast, E2F5–8
are considered to predominantly be transcriptional repressors.
Their biological functions are mainly associated with differ-
entiation and apoptosis [1,2].
The transcriptional activity and specificity of the E2F
family members is tightly regulated via multiple mechan-
isms. During cell progression, the ability of E2F1–5 to
regulate transcription is controlled by the retinoblastoma
protein (pRb) pathway, mainly through association of E2F to
pRb: the binding of pRb to the C-terminal transactivation
domain of E2F inhibits E2F activity [3]. Phosphorylation of
pRb by cyclin D-dependent kinase results in the dissociation
of pRb from the E2F·DP complex, allowing E2F to activate
transcription of target genes. Members of the retinoblastoma
protein family can also activate apoptosis through modula-
tion of E2F1 activity [2]. E2F1-driven apoptosis can be
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dependent and p53-independent pathways [4,5]. E2F6–8
do not bind to pRb proteins; however, E2F6 interacts and
forms complexes with polycomb proteins [6].
E2F activity is also regulated by post-translational
mechanisms, such as phosphorylation and/or acetylation.
Phosphorylation of E2F1 by ATM and Chk2 kinases
stabilizes and increases E2F transcriptional activity in
response to DNA damage [7]. E2F1 is also phosphorylated
by cdk7 which results in its ubiquitination and subsequent
degradation [8]. Moreover, acetylation of E2F1–3 by the
p300/CBP acetyltransferase leads to an enhanced DNA
binding affinity that stimulates its transcriptional activity
[9,10].
External stimuli regulate E2F activity by activating
different signal transduction pathways. Previous results
obtained by others and by our group have demonstrated
that activation of the phosphatidylinositol 3-kinase/protein
kinase B (PI 3-kinase/PKB) pathway changes E2F-regulated
transcriptional activity indirectly through its targets [11–13].
However, there is so far no evidence for the E2F
transcription factor to be a direct target of PKB downstream
effectors. One of the direct PKB downstream effectors is the
glycogen synthase kinase-3β (GSK3β) [14]. For years
GSK3β was considered to be a protein kinase whose
function was confined to glycogen metabolism. Only
recently, the study of this kinase has become a new focus
since it has been implicated in several other biological
processes regulated by PKB, such as regulation of
metabolism, protein synthesis and cell cycle [11,15,16].
During the cell cycle, GSK3β indirectly regulates E2F
activity by phosphorylating cyclin D1 triggering its degrada-
tion [16]. At the transcriptional level, GSK3β indirectly
regulates cyclin D1 expression by phosphorylation and
degradation of its transcription factor β-catenin [17].
The indirect regulation of E2F activity by GSK3β
through cyclin D does not exclude other mechanisms of
action. For example, cyclin D does not act as a direct G1/S-
phase regulator in Drosophila [18], suggesting the existence
of another regulatory mechanism of E2F activity. Here, we
demonstrate that GSK3β directly regulates E2F transcrip-
tional activity. Surprisingly, our data reveal that the kinase
activity of GSK3β is not required to exert this control.
Much more, binding of GSK3β to E2F1 appears to be the
mode of action how GSK3β regulates E2F1 transcriptional
activity.
2. Materials and methods
2.1. Materials
Fetal calf serum, Dulbecco's modified Eagle's medium (DMEM), and
penicillin/streptomycin and Lipofectamine TM2000 Transfection Reagent
from GIBCO BRL. [γ-32P] dATP (3000 mCi/mmol), 32Pi-ortophosphate
(10 mCi/ml) Hybond-N membranes and ECL chemiluminescence reagent
were supplied by Amersham-Pharmacia. SB 216763 and SB 415286 were
purchased from Tocris. LY 294002, DRB, protein A–sepharose and protein
G–sepharose from Sigma. Galactosidase and luciferase assay systems weresupplied by Promega. Phospho-glycogen synthase peptide-2 came from
Upstate Biotechnology. Anti-E2F1, anti-polyhistidine, anti-GST antibodies
were purchased from Santa Cruz Biotechnology. Anti-GSK3β, β-catenin
antibodies came from BD Transduction Laboratories. Anti-α-tubulin came
from Oncogen and hemagglutinin epitope antibody from Roche. Other
materials and chemicals were of the highest quality available.
2.2. Constructs and recombinant proteins
Adenovirus expression vector wild-type (Ad-WT-GSK3β), catalytically
inactive (Ad-KM-GSK3β) and uninhibitable (Ad-S9A-GSK3β) forms of
GSK3β were kindly provided by Dr. M. Birnbaum (University of
Pennsylvania, USA). pcDNA-GSK3β constructs were generated by standard
PCR and cloning methods. Coding region of GSK3β was amplified from
GSK3β adenovirus expression vectors and introduced into XhoI and NotI
sites of pcDNA3(−) vector or pCMV/myc/nuc to obtain either cytoplasmic
or nuclear GSK3β constructs. [E2F]3-Luc and HA-E2F1 constructs were
kindly provided by Dr. M. Gstaiger (Friedrich-Miescher-Institut, Basel,
Switzerland). GST-E2F1 was kindly donated by Dr. E. Lam (Imperial
Cancer Research, London, UK). GAL4-E2F1(AD) fusion protein gene
(amino acids 380–437), and mutated 403 and 433 forms, wild-type GST-
hE2F1(AD), and mutated 403 and 433 forms were kindly provided by Dr.
Kouzarides (University of Cambridge, UK). Bacterially expressed proteins
were produced in E. coli and isolated using standard GST fusion protein
protocols (Pharmacia).
2.3. Cell culture, transfections and adenovirus infection
HEK293T and HeLa cells were cultured at 37 °C in 5% CO2, in
Dulbecco's modified Eagle medium (DMEM), which contained 10% fetal
bovine serum and 1% penicillin–streptomycin. Transient transfections were
performed using the calcium phosphate/DNA co-precipitation method, or
liposome-mediated transfection (lipofectamine). When applying the calcium
phosphate/DNA, co-precipitation method cells were plated in 4×105 cells/
35-mm culture dish and transfection was performed as previously described
[12]. Lipofectamine cells were transfected according to the manufacturer's
instructions. Each plate contained pCMV5 β-galactosidase expression
vectors as an internal control and the total amount of plasmid was adjusted
with empty pcDNA3(−) expression vector. Adenovirus infection was
normalized according to protein expression. Hela cells (2.5×105 cells/p35
well) were transduced with the adenovirus GSK3β constructs and incubated
for 48 h before being lyzed.
2.4. GSK3β knockdown
GSK3β was knocked down by GSK3β siRNA transfection, using the
lipofectamine method. GSK3β siRNA used: 5′-GAUCCUGUCUUGAAG-
GAGAAdTdT-3′ sense strand and 5′-UUCUCCUUCAAGACAGAUCdGdG-
3′ antisense strand, Scramble siRNA :5′-UUCUCCGAACGUGUCACGUd-
TdT-3′ sense strand and 5′-ACGUGACACGUUCGGAGAAdTdT-3′ anti-
sense strand was used as a negative control. Both oligos were purchased
from Quiagen. Each plate contained pCMV5-renila expression vectors as an
internal control.
2.5. P-orthophosphate labeling in cells
HeLa cells were washed three times in phosphate-free RPMI medium
and exposed to 200 μCi/ml of [32P]orthophosphate for 5 h in the presence
or absence of inhibitors. After treatment, cells were washed four times with
cold TBS buffer (20 mM Tris–HCl [pH=8.3], 137 mM NaCl) and lysed in
50 mM Tris–HCl [pH=8], 150 mM Na Cl, 1 mM EDTA, 1% NP-40,
1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 1 mM
NaF and 1 μg/ml of aprotinin, leupeptin and pepstatin. After lysates were
clarified, E2F1 was immunoprecipitated with anti-E2F1 (Santa Cruz) protein
A–sepharose-32P incorporation into E2F1 was visualized after sodium
dodecyl sulfate-10% polyacrylamide gel electrophoresis, and transfer to
polyvinylidene difluoride (PVDF) membrane by autoradiography.
Fig. 1. In vitro phosphorylation of GST-E2F1 constructs by GSK3β. 3 μg
of different GST fusion proteins (A): human E2F1 protein; (B): wild type
and mutants transactivation domain were phosphorylated in vitro, with
purified GSK3β 60μU. The reaction products were resolved in a 15%
SDS-polyacrylamide gel and the phosphorylated proteins visualized by
autoradiography.
377G. García-Alvarez et al. / Biochimica et Biophysica Acta 1773 (2007) 375–3822.6. In vitro phosphorylation
GST-expressed proteins were incubated with [γ.32P] ATP (40 μCi,
3000 mCi/mmol), ATP (10 μM) in a buffer containing 20 mM HEPES
(pH=8), 10 mM MgCl2 and 1 mM EDTA in the presence of purified GSK3β
60 μU, Sigma) for 30 min. The reaction products were resolved on sodium 15%
SDS-PAGE, and the phosphorylated proteins were visualized by autoradio-
graphy. Protein loading was checked by Coomassie blue staining.
2.7. Immunoprecipitation, co-immunoprecipitation and
immunoblotting
Cells were washed twice with ice-cold phosphate-buffered saline (PBS), and
lysed with RIPA buffer (50 mMTris–HCl [pH=8], 150 mMNaCl, 1 mMEDTA,
1% NP-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate,
1 mM NaF and 1 μg/ml of aprotinin, leupeptin and pepstatin). After
centrifugation, equal amounts of protein (200 μg for immunoprecipitation or
3 mg for co-immunoprecipitation) were immunoprecipitated using 2 μg of the
corresponding antibody, followed by protein G–sepharose to immunoprecipitate
endogenous GSK3β, and E2F1 and protein A–sepharose for HA-tagged E2F1.
Cells were then incubated for 1 h at 4 °C, under continuous shaking. Pellets were
washed three times with ice-cold RIPA buffer for immunoblotting, or with kinase
buffer (16 mMMOPS [pH=7,4], 100 mM β-glycerolphosphate, 0,4 mMEDTA,
20 mMmagnesium acetate, 2 mMNaF 1 mM benzamide, 2 μg/ml aprotinin) for
measuring GSK3β activity. For immunoblotting, proteins were resolved in 10%
SDS-PAGE, then transferred to membranes and probed with antibodies to
GSK3β (BD Transduction Laboratories), E2F1 (Santa Cruz), and tubulin (Santa
Cruz). Immunoblots were developed using horseradish peroxidase-conjugated
antibodies, followed by detection with enhanced chemiluminescence.
2.8. Identification of E2F1 residues phosphorylated by GSK3β
1 mg of GST-hE2F1 was phosphorylated in vitro by GSK3β. The sample
was resolved in 10% SDS-PAGE and the phospho-GST-hE2F1 band was
excised from the gel, reduced with DTT, alkylated with iodoacetamide and
cleaved with trypsin (Promega, sequencing grade), as previously described
[19,20]. An AspN cleavage was then performed (Boehringer). Peptides were
extracted, fractionated and analyzed by liquid chromatography, interfaced with
electrospray mass spectrometry (LC-MS). A Rheos 4000 chromatograph was
used, equipped with a 1×250 mm Vydac (Hesperia, CA) C8 column and
interfaced with a Sciex API 300 mass spectrometer (PE Sciex, Toronto,
Ontario, Canada), employing the single quadrupole operating mode. The
column was equilibrated in 95% solvent A (2% CH3CN, 0.05% TFA in H2O),
5% solvent B (80% CH3CN, 0.045% TFA in H2O), and a linear gradient was
developed from 0 to 50% solvent B in 60 min at a flow rate of 0.05 ml/min as
previously described [21]. NanoESI mass spectrometry (MS) was performed
according to the published method of Carr et al. [22]. The masses of the
phosphopeptides were identified by 79 Da precursor-ion scanning in the
negative ion mode. The mass spectra were acquired on API 300 triple
quadrupole mass spectrometer (PE Sciex, Toronto, Ontario, Canada), equipped
with a NanoESI source (Protana, Odense, Denmark), or on a Iontrap Deca XP
(Thermo Finnigan, San Jose, CA).
2.9. GSK3β activity
GSK3β activity was measured as previously described [23]. Briefly, GSK3β
was immunoprecipitated and activity measured by incubation in 40 μl of kinase
buffer with [γ.32P] ATP (40 μCi, 3000 mCi/mmol), ATP (10 μm) with 15 μM of
phospho-glycogen synthase petide-2 (Upstate Biotechnology) for 30 min at
30 °C. 25 μl of samples was then spotted into p81 phosphocellulose paper and
washed three times with cold 0.75% phosphoric acid. The incorporated
radioactivity was measured by a scintillation counter.
2.10. Others
Silico prediction was achieved using the Scansite program. Comparison
between experimental groups was made by Student's unpaired t test. Differenceswere indicated by *p<0.08 and **p<0.008. Each experiment was performed at
least three times, and the group data were expressed as mean±S.E.
3. Results
3.1. GSK3β phosphorylates E2F1 at serine 403 and
threonine 433
In silico analysis of human E2F1 predicted several
potential phosphorylation sites for GSK3β. In order to test
whether E2F1 was indeed a substrate of GSK3β we
performed an in vitro kinase assay using E2F1-glutathione
S-transferase (GST)-fusion protein. GST protein served as
a negative control. As shown in Fig. 1A, a unique band of
94 kDa was detected, which corresponds to the phosphory-
lated purified GST-hE2F1. In contrast and as expected, no
signal was detected for the purified GST protein alone.
We mapped the phosphorylated sites by liquid chromato-
graphy and mass spectrometry analysis. GST-hE2F1 was
phosphorylated in vitro by GSK3β and cleaved with trypsin
and AspN digestions. The analysis of the fractionated
peptides obtained showed two main peaks of phosphopep-
tides. The calculation of the mass weight of the phospho-
peptides by spectrometry analysis was consistent with the
DLpT433PL and EDFSGLLPEEFISLpS403PPHEAL peptides.
To test whether serine 403 and threonine 433 are the
residues phosphorylated by GSK3β, we performed in vitro
phosphorylation experiments using a truncated and mutated
form of E2F1. We used a GST fusion protein containing the
putative GSK3β phosphorylation sites in human E2F1
transactivation domain (amino acids 380–437) with none,
one, or two point mutations, respectively. As shown in Fig.
1B, GSK3β phosphorylates E2F1 at the active domain, in
accordance with the localization of both amino acids within
this domain. Mutation of serine 403 almost abolished this
phosphorylation and mutation of threonine 433 also reduced
it, although to a lesser extent. Double mutation completely
inhibited the phosphorylation. The integrity of the fusion
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Interestingly, serine 403 and threonine 433 are also targets of
phosphorylation by cdk7, a kinase component of the TFIIH
complex [8]. Therefore, cdk7 and GSK3β are good candidates
for E2F1 phosphorylation in vivo. In order to determine the
extent to which these kinases are responsible for the endo-
genous phosphorylation, HeLa cells were radioactively labeled
with 32P-orthophosphate and formation of phospho-E2F1 was
analyzed in the presence or absence of cdk7 and GSK3β-
specific inhibitors, 5,6-dichloro-1-β-D-ribofuranosylbenzimida-
zole (DRB) and SB216763, respectively. DRB is an adenosine
analogue that inhibits RNA polymerase II elongation by
inhibiting the TFIIH-associated kinase, cdk7 [24]. SB216763
is an ATP-competitive inhibitor of GSK3β [25]. In addition, LY
294002, an inhibitor of PI 3-kinase activity, was used to activate
endogenous GSK3β activity [26]. It is known that GSK3β
activity is negatively regulated by PKB-mediated phosphoryla-
tion, a positive target of the PI 3-kinase activity. The results
shown in Fig. 2 demonstrate that neither inhibition of PI 3-
kinase nor endogenous GSK3β produced a relevant change on
endogenous E2F1 phosphorylation. In contrast, the phosphor-
ylation signal was abrogated by treatment with DRB, confirm-
ing the role of cdk7 in E2F1 phosphorylation. Whether GSK3β
phosphorylates E2F1 in vivo was also analyzed in cells
overexpressing GSK3β [27]. Cells infected with GSK3β
adenovirus constructs yielded a level of E2F1 phosphorylation
comparable to that of endogenous GSK3β (data not shown).
These results suggest a predominant role of cdk7 in the effect of
GSK3β on E2F1 phosphorylation.
3.2. E2F1 and GSK3β bind in vivo
The phosphorylation of E2F1 by GSK3β suggested that the
two proteins physically interact. To investigate the existence of
in vivo binding we performed co-immunoprecipitation experi-
ments in HEK293T cell extracts. Cells were transiently co-
transfected with both an E2F1 (E2F1-HA) expression vector
and one of the following GSK3β expression vectors: anFig. 2. Effect of SB 216763, Ly 294002 and DRB on the phosphorylation of
endogenous E2F1. Two hours before radioactive orthophosphate (200 μCi/ml)
was added, HeLa cells were incubated with indicated amounts of inhibitors.
Cells were incubated for 5 h, and E2F1 protein was then immunoprecipitated
using anti-E2F1 antibody. Products were resolved in a 12% SDS-polyacryla-
mide gel. Phosphorylated proteins were visualized by autoradiography (upper
panel). E2F1 immunoprecipitated and GSK3β overexpression were evaluated
by blotting against E2F1 (middle panel) and GSK3β protein (lower panel),
respectively. “C” stands for control where the immunoprecipitation was done
from a mixture of all other extracts using antibody against the His tag.uninhibitable form (S9A-GSK3β), that contains an amino acid
exchange in the GSK3β regulatory site of serine to alanine at
position 9, an inactive form (KM-GSK3β), containing two
point mutations in the kinase domain, or a wild-type form (WT-
GSK3β). After 48 h of transfection, cells were harvested and
cell extracts were prepared. The levels of E2F1 and GSK3β
were measured by immunoblot analysis. Then, E2F1 was
immunoprecipitated using a polyclonal antibody against the HA
tag and, as a negative control, against histidine tag. The levels of
immunoprecipitated E2F1 and of co-immunoprecipitated
GSK3β were measured. The results are shown in Fig. 3A.
The expression levels of E2F1 and GSK3β in the total extract
were similar under all the conditions. We interpreted the slightly
lower mobility of the expressed versus the endogenous GSK3β
detected on the PAGE as an effect caused by the ten C-terminal
extra residues present in the vector construct. Under all the
conditions where HA-tag antibody was used to immunopreci-
pitate, equal amounts of E2F1 were detected in the pellet. Co-
immunoprecipitated GSK3β was found in all the conditions
except when cell extracts were immunoprecipitated with an
antibody against the histidine tag (Fig. 3A, condition C).
Interestingly, the amount of co-immunoprecipitated GSK3β
detected was similar for the wild-type (WT-GSK3β), the
uninhibitable (S9A-GSK3β) and the inactive (KM-GSK3β)
forms of GSK3β, and proportional to its expression level. The
absence of tubulin immunoreactivity in the immunoprecipita-
tion products indicates an absence of supernatant protein
contamination (Fig. 3B). These results are consistent with the
hypothesis that the association of E2F1 with GSK3β is not
mediated by GSK3β kinase activity. GSK3β activity was also
measured in the cell extracts to ensure that the GSK3β
constructs were working properly (Fig. 3C).
To confirm the physical association between E2F1 and
GSK3β, we tested whether E2F1 also co-immunoprecipitated
when using an antibody against GSK3β. Cells were transfected
under the same conditions as described above, and E2F1
immunoreactivity was measured in the GSK3β immunopreci-
pitate. As shown in Fig. 4, panel A, co-immunoprecipitated
E2F1 was found under all the conditions, except when cell
extract was immunoprecipitated with antibody against GST tag.
Consistent with the nature of constitutive endogenous interac-
tion, changes in GSK3β activity did not disturb binding to
E2F1. Absence of tubulin immunoreactivity was also detected
in the immunoprecipitation products (Fig. 4B).
3.3. Functional regulation of E2F1 by GSK3β
In vitro phosphorylation assays showed that serine 403 and
threonine 433 were the two residues phosphorylated by
GSK3β. Due to the localization of both amino acids in the
E2F1 transactivation domain, we wanted to test whether
GSK3β modulates E2F1 transcriptional activity through
interaction with this domain. To this end, we used a reporter
system based on two plasmids. The first plasmid, GAL4-E2F1
(AD), encodes for a fusion protein with the DNA-binding
domain of GAL4 and the transactivation domain of E2F1
(amino acids 380–437). The second plasmid contains the
Fig. 4. Detection of E2F1 in the GSK3β immunoprecipitated. HEK293T
cells (4×105 cells/35-mm culture dishes) were transiently transfected with
5 μg of HA-E2F1 and 15 μg of the indicated GSK3β constructs by calcium
phosphate method. 48 h after transfection, equal amounts of whole cell
extract (3 mg) were subjected to co-immunoprecipitation of GSK3β protein
using a monoclonal antibody against GSK3β (IP). “C” stands for control
where the immunoprecipitation was done from a mixture of all transfection
conditions, using a monoclonal antibody against GST tag (A and B).
Expression of GSK3β and E2F1 was assessed by Western blot on the
whole extract (two upper lines of panel A). Immunoprecipitation of E2F1
was also assessed by immunoblotting. (B) Expression of tubulin was
assessed by Western blot on the immunoprecipitated.
Fig. 5. Modulation of the E2F1 transcriptional domain by overexpression of
S9A-GSK3β and KM-GSK3β (4×105 cells/35-mm culture dishes) were
transiently transfected with 0.3 μg GAL4-luciferase, 0.3 μg of pCMV-β-
galactosidase, 0.1 μg Gal4-E2F1(AD) or 0.1 μg pGal4-VP16, together with 1 μg
of the indicated GSK3β constructs by calcium phosphate method. 48 h after
transfection, luciferase activity was measured, and the values were correlated for
relative β-galactosidase milliunits and expressed as arbitrary units. Data are
presented as means of three independent conditions. Statistically significant
differences were calculated comparing cell conditions in the absence of
overexpression of GSK3β.
Fig. 3. Detection of GSK3β in the E2F1 immunoprecipitated. HEK293T cells
(4×105 cells/35-mm culture dishes) were transiently transfected with 5 μg of
HA-E2F1 and 15 μg of the indicated GSK3β constructs by calcium phosphate
method. 48 h after transfection, equal amounts of whole cell extract (3 mg) were
subjected to co-immunoprecipitation of E2F1 protein using a polyclonal
antibody against HA tag (IP). “C” stands for control where the immunopreci-
pitation was done from a mixture of all transfection conditions, using a
polyclonal antibody against His tag (A and B). Expression of GSK3β and E2F1
was assessed by Western blot on the whole extract (two upper lines of panel A).
Immunoprecipitation of E2F1 was also assessed by immunoblotting. (B)
Expression of tubulin was assessed by Western blot on the immunoprecipitated.
(C) 200 μg of cell extract was immunoprecipitated with GSK3β antibody and in
vitro GSK3β kinase assay was performed as described in Materials and
methods.
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GAL4 DNA binding domain. Luciferase activity was measured
in the transfected HEK293T cell line in the presence or absence
of either the uninhibitable (S9A-GSK3β), or the inactive (KM-
GSK3β) GSK3β expression plasmids. As shown in Fig. 5,
overexpression of GSK3β reduced the levels of luciferase
activity. Both GSK3β mutants (S9A and KM) inhibited E2F
transcriptional activity with similar efficiency, suggesting that
this modulation was independent of GSK3β kinase activity.
These results suggest that GSK3β is able to modulate E2F1
transcriptional activity through its interaction with the transac-
tivation domain.
E2F1 has been described as primarily localized in the
nucleus in cycling cells; whereas GSK3β is localized mainly in
the cytoplasma [28]. An increase in nuclear GSK3β has been
previously detected during G1/S- and S-phase in different cell
Fig. 7. Effect of GSK3β knockdown by siRNA. HEK293T cells (1×105 cells/
35-mm culture dishes) were transfected with 1 μg of [E2F]3-luciferase, 1 μg of
HA-E2F1 and 0.5 μg of CMV-Renilla and the indicated concentrations of
GSK3β siRNA or scramble siRNA. Cells were harvested 2 days after
transfection. Luciferase activity was measured, and the values were correlated
for relative renilla activity. Data are presented as means of three independent
conditions and expressed as relative luciferase units. Statistically significant
differences were calculated by comparing cell conditions in the presence of
siGSK3β with scramble siRNA.
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withdrawal or DNA damage [29,30]. Taking this into account,
we examined whether nuclear localization of GSK3β would
affect its action on E2F1. We cloned the uninhibitable and
catalytically inactive form of GSK3β into plasmids containing a
nuclear localization signal (S9A-GSK3β-nuc and KM-GSK3β-
nuc), and measured its effect on E2F1 activity using the same
system described above. The re-targeting of the GSK3β protein
and GSK3β activity was confirmed (data not shown). To verify
the specificity of the interaction between GSK3β and the
transactivation domain of E2F1, we measured the effect of the
nuclear GSK3β form on the transactivator domain of the herpes
virus VP16, using the fusion protein GAL4-VP16 as a negative
control. The results shown in Fig. 5 demonstrate that nuclear
localization of GSK3β inhibited luciferase activity to a greater
extent than the cytoplasmic form. In contrast, we found no
significant change in luciferase activity in GAL-VP16 trans-
fected cells. These results suggest that GSK3β regulates E2F
activity through its translocation to the nucleus.
To determine whether serine 403 and threonine 433 are
essential for the regulation of E2F activity by GSK3β, we
examined the ability of GSK3β to modulate the transcriptional
activity of a fusion protein with the DNA-binding domain of
GAL4 protein and the E2F1 transactivation domain, where both
amino acids were mutated to alanine (S403A/T433A). The
results obtained are shown in Fig. 6 and reveal that double
mutation S403A/T433A at the transactivation domain of E2F1
does not change the effect of GSK3β in regulating the luciferase
transcription of the GAL4-luciferase system. These results
strongly suggest that phosphorylation of serine 403 and
threonine 433 are not involved in the regulation of E2F
transcriptional activity by GSK3β.Fig. 6. Role of serine 403 and threonine 433 on the regulation of E2F1
transcriptional domain by overexpression of S9A-GSK3β and KM-GSK3β.
(4×105 cells/35-mm culture dishes) were transiently transfected with 0.3 μg
GAL4-luciferase, 0.5 μg of pCMV-β-galactosidase, 0.1 μg pGal4-E2F1(AD) or
0.1 μg pGal4-E2F1(AD) S403A/T433A, together with 1 μg of the indicated
GSK3β constructs by calcium phosphate method. 48h after transfection
luciferase activity was measured and the values were correlated for relative β-
galactosidase milliunits and expressed as relative luciferase units. Data are
presented as means of three independent conditions. Statistically significant
differences were calculated by comparing cell conditions in the absence of
overexpression of GSK3β.Our results indicate that direct modulation of E2F1 by
GSK3β is independent of its kinase activity. To investigate
whether transcriptional activity of E2F1 could be affected by
GSK3β protein concentration, we used RNA interference to
knockdown GSK3β in HEK293Tcells. These cells were chosen
because they synthesize E1A and SV40 T antigen and can
therefore preclude the regulation of E2F1 activity by the pRb/
cdk pathway [31]. Thus, the indirect effect of GSK3β on E2F1
activity through the regulation of the levels of cyclin D could be
reduced. HEK293T cells were transfected with a luciferase
reported gene under the control of an E2F regulated promoter
([E2F]3-Luc), together with HA-E2F1 plasmid, and in the
presence of GSK3β small interfering RNA (siRNA) or
scramble siRNA. Luciferase activity was determined and the
results are summarized in Fig. 7. Transfection with GSK3β
siRNA reduced the levels of the protein by up to 65%; in
contrast, luciferase activity increased by almost 50%. This result
strongly demonstrates that the presence of GSK3β protein can
inhibit E2F transcriptional activity. Taking this result together
with the demonstration that regulation of E2F1 by GSK3β is
independent of its kinase activity suggests that modulation of
E2F1 activity by GSK3β occurs through physical protein
interaction between both proteins.
4. Discussion
Whether a cell enters into the cell cycle, undergoes apoptosis
or survives is a consequence of the integration of several
cellular and environmental signals. Growth factors, cell contact,
and apoptotic inductors regulate a complex system of signal
transduction pathways that trigger the activation of a large
number of genes. The transcription factor E2F1 is one of the key
381G. García-Alvarez et al. / Biochimica et Biophysica Acta 1773 (2007) 375–382proteins in the regulation of the cell cycle and the commitment
to apoptosis. It has been suggested that E2F1 activity levels
determine whether a cell enters cell cycle arrest or apoptosis [1–
3]. E2F transcriptional activity and the synchronization of this
activity with specific signal transduction pathways may play
crucial roles in these cell fate decisions. In this context it has
been suggested that activation of the PI 3-kinase pathway
inhibits the apoptotic effect of E2F1 overexpression [32]. Our
studies focused on the role of GSK3β, a downstream effector of
PI 3-kinase, as a direct regulator of E2F transcriptional activity.
In silico analysis of human E2F1 predicted several
potential phosphorylation sites for GSK3β. Our results
confirmed these predictions in vitro, and we were able to
identify serine 403 and threonine 433 as the target residues
by mass spectrometry analysis. The role of these residues
was confirmed by mutation analysis. Interestingly, both
serine 403 and threonine 433 of E2F1 are also phosphory-
lated by the complex cyclin H-cyclin-dependent kinase 7
(cdk7), one of the components of the RNA polymerase II
transcription factor TFIIH [8]. TFIIH is a multifunctional
complex involved in both transcription and DNA repair,
which phosphorylates RNA pol II and nuclear receptors. It
has been demonstrated that TFIIH-mediated phosphorylation
of E2F1 plays a role in triggering E2F1 degradation during
S-phase. TFHII binds to E2F1 specifically in S-phase in
vivo and results in E2F1 phosphorylation and rapid
degradation [8]. Our results suggest that GSK3β does not
phosphorylate E2F1 in vivo. Possibly, TFHII might be a
candidate that phosphorylates E2F1.
Inhibition of Cdk7 leads to a significant reduction of E2F1
phosphorylation; in contrast, inhibition of GSK3β did not alter
E2F1 phosphorylation. We cannot exclude a possible
phosphorylation of E2F1 by GSK3β in vivo since different
kinetic behavior in the phosphorylation of E2F1 by cdk7 and
GSK3β and/or limited sensitivity of the assay cannot formally
be ruled out. It has been suggested that a kinase other than
cdk7 could contribute to the phosphorylation of E2F1 during
middle G1 and G2 phases in Hela cells [8]. The pattern of
E2F1 phosphorylation during the cell cycle does not correlate
with the binding of TFHII to E2F1 [8,33]. In addition,
immunodepletion of cdk7 reduces only 70% of E2F1
phosphorylation [8]. GSK3β might be responsible for the
remaining 30%.
Our study demonstrates that GSK3β physically interacts
with E2F1 in vivo, and that this binding is independent of
GSK3β kinase activity. Uninhibitable (S9A-GSK3β) and
catalytically inactive (KM-GSK3β) forms of GSK3β bind
to E2F1 in quantities comparable to the wild type. Binding
experiments were conducted in the presence of FCS;
conditions in which GSK3β is phosphorylated at serine 9
by PKB. It has been reported that this phospho-serine
occupies the same pocket as the priming phosphate
necessary for some substrates to access the GSK3β active
site [34]. The fact that phosphorylation in serine 9 at the
amino terminus tail does not derogate E2F1 binding to
GSK3β, supports the idea that E2F1 binds GSK3β at a
different site to the primed substrates. Binding sites otherthan those bound by the primed substrates were proposed
for other proteins. This was the case with Axin and FRAT,
which both bind to the C terminal domain of GSK3β
[35].
The binding of GSK3β to E2F1 transactivation domain,
suggests that the GSK3β binding could affect E2F1
transcriptional activity. We demonstrated that GSK3β inhibits
transcriptional activity of a fusion protein containing DNA-
binding domain of GAL4 protein and the E2F1 transactiva-
tion domain. Interestingly, kinase activity was not required for
this regulation, suggesting that modulation occurs by protein–
protein interaction. Furthermore, this interaction appears
independent of the phosphorylation state of serine 403 and
threonine 433 In support of this model, we found that
knockdown of GSK3β by siRNA clearly showed an
activation of E2F transcriptional activity, which was propor-
tional to the reduction of GSK3β protein. Translocation of
GSK3β from the cytoplasm to the nucleus could be the
mechanism that is required for the regulation of E2F activity.
Several reports support this hypothesis. During the S-phase,
an accumulation of GSK3β was detected in the nucleus,
indicating the role of this kinase during this phase [36]. The
subcellular localization of GSK3β has been described to be
dependent on the PI 3-kinase pathway, but independent of the
phosphorylation state of serine 9 and/or tyrosine 216 amino
acids essential for the regulation of GSK3β activity [29].
Because GSK3β had neither a nuclear localization signal nor
a nuclear export signal, the PI 3-kinase could have been
regulating the binding to GSK3β of some importing or
exporting proteins. In agreement with the role of GSK3β
localization on E2F regulation, we demonstrated that unin-
hibitable and catalytically inactive GSK3β forms containing a
nuclear localization signal showed a higher capacity to
regulate E2F transcriptional activity than their cytoplasmic
homologues.
Until at present, it has been accepted that the regulation
of E2F activity by GSK3β was indirect, through the action
of this kinase on levels of cyclin D1. GSK3β phosphory-
lates cyclin D1 which increases cyclin D1 degradation [16].
Moreover, GSK3β indirectly regulates cyclin D1 expression
by phosphorylation and degradation of its transcription
factor β-catenin [17]. Under these conditions, cdk4/6
activities are low and Rb inhibits E2F activity. These data
reveal a second pathway where GSK3β directly regulates
E2F activity by physical interaction with the transactivation
domain of E2F1. Both processes could act independently
and according with the state of the cell cycle.
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